Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Hemophilia A Gene Therapy Race Intensifies With Updated Sangamo/Pfizer Data

GeneTherapy

Related Content

BioMarin CEO Suggests Hemophilia Gene Therapy Pricing In $2m-$3m Range

Feb 22 2019

Roche $4.8bn Buy Sparks Hemophilia Gene Therapy Race

Feb 25 2019

J.P. Morgan Notebook Day 3: Biotech Feeling Government Shutdown, AstraZeneca, Denali, Allergan, Aptinyx, Sangamo

Jan 10 2019

Related Companies

Sangamo Therapeutics, Inc.

Pfizer Inc.

BioMarin Pharmaceutical Inc.

Spark Therapeutics, Inc.

Roche Holding AG

Sanofi

Additional Topics

Gene Therapy Rare Diseases Regenerative Medicine Research & Development Blood & Coagulation Disorders BioPharmaceutical

More from Gene Therapies

More from Advanced Therapies

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window